FGEN Share Price Performance
US$10.55
1.62 (18.11%)
75.5% undervalued intrinsic discount
US$43.00
Fair Value
Price US$10.55
AnalystConsensusTarget US$43.00
Fair ValueUS$43.00
Share PriceUS$10.55
75.5% undervalued intrinsic discount
FibroGen, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
FGEN Community Narratives
AN
Fair Value US$43 73.5% undervalued intrinsic discount
Clinical Trials And Regulatory Advances Will Open US Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
FibroGen, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -21.61
- Gross Margin
- -394.13%
- Net Profit Margin
- -1,189.84%
- Debt/Equity Ratio
- -51.4%
FibroGen, Inc. Competitors
Snowflake Analysis
About FGEN
- Founded
- 1993
- Employees
- 225
- CEO
- WebsiteView website
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -2.8%
- 3 Months: 5.3%
- 1 Year: 13.4%
- Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a decline of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›